ALLCURES.COM(2006) LIMITED
Company number 06061808 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: ALLCURES.COM(2006) LIMITED
1. Financial Health Score: C — Fair / Guarded
The company is registered as active, up to date with its filings, and technically solvent (net assets remain positive). However, it operates with a very thin capital cushion, minimal cash cover against short-term debts, and an explicit reliance on support from its parent group. In medical terms, the patient is conscious and stable for now, but is dependent on an intravenous drip from the parent company and has little reserve strength to withstand a sudden shock.
2. Key Vital Signs
| Vital Sign | Latest Reading (2023) | Prior Reading (2022) | Interpretation |
|---|---|---|---|
| Net Assets (equity cushion) | £183,891 | £230,667 | Very low relative to a £22.5 million balance sheet. The cushion shrank by roughly £47,000, indicating a loss in the latest year. Like low bone density, this offers little protection against future setbacks. |
| Cash at bank | £244,192 | £11,873 | Cash improved markedly, but still represents only about 2% of current liabilities. The pulse is present but weak. |
| Current Ratio (Current assets ÷ Current liabilities) | ~1.34 | ~2.58 | Short-term assets still exceed short-term debts, but the buffer has narrowed significantly. A ratio above 1 is reassuring, yet the downward trend is a symptom to watch. |
| Cash Ratio (Cash ÷ Current liabilities) | ~0.02 | ~0.004 | Extremely low. If all creditors demanded payment at once, cash would cover only a small fraction. |
| Net Current Assets (working capital) | £4.14 million | £4.71 million | Positive working capital, but it has contracted. The company has day-to-day headroom, though less than before. |
| Equity as % of Total Assets | ~0.8% | ~1.7% | The company is highly leveraged and funded mostly by liabilities rather than owners’ funds. This is a thin capital base for a business of this size. |
| Group Dependency | Debtors include £15.05 million owed by group undertakings; creditors include £10.36 million owed to group undertakings. The accounts state the company is reliant on group support to continue as a going concern. | Debtors included £6.74 million owed by group; creditors included £0.31 million owed to group. | The balance sheet is increasingly entangled with the parent group. Money is owed to and by group companies, meaning operational strength is closely tied to the group’s own health. |
| Filing Compliance | No overdue accounts or confirmation statements. | No overdue filings. | Good. The company keeps its regulatory “check-ups” current. |
3. Diagnosis
Overall condition: Solvent but fragile.
The business is not in immediate collapse. It is active, net assets are positive, and statutory filings are up to date. Nevertheless, several symptoms point to underlying weakness:
- Thin capitalisation: Shareholders’ funds of roughly £184,000 against total assets of £22.5 million mean the company has very little of its own money at risk. A relatively small trading loss or asset write-down could erode equity quickly.
- Weak liquidity: Cash covers only a small percentage of creditors due within one year. The company appears to rely on the timing of collections—particularly from group companies—to meet obligations as they fall due.
- Group dependence: The accounts themselves state that the company is reliant on group support for the foreseeable future. Large balances owed by group undertakings are an asset on paper, but they are only as good as the paying ability of those group companies. At the same time, substantial amounts are owed to group undertakings, creating a close financial tether.
- Recent loss: The profit and loss reserve fell from £46,776 to nil, and net assets fell by a corresponding amount, indicating the company operated at a loss in the latest reported year. No profit and loss account was included in the filed abridged statements, but the movement in reserves signals a negative result.
In short, the company resembles a patient whose vital signs are currently within acceptable limits but who remains dependent on external support and lacks a robust reserve of strength.
4. Recommendations
-
Build a cash buffer.
Aim to increase cash holdings so that short-term obligations can be met without depending entirely on collections from group companies. Even a modest reserve would improve the “pulse” of the business. -
Formalise intercompany arrangements.
Given the large debtor and creditor balances with group undertakings, clear repayment terms and interest arrangements should be documented. This reduces uncertainty about when cash will actually arrive or be required. -
Address the recent loss.
Review pricing, procurement costs, and overheads in the pharmaceutical wholesale operation. Since the directors elected not to file a profit and loss account, management should prepare internal monthly profitability reports to identify where margin is being lost. -
Reduce reliance on the parent group.
Explore alternative funding sources (e.g., external credit facilities, invoice financing, or retained earnings) so the company is not solely dependent on group support for its going-concern status. -
Monitor working capital closely.
Debtors more than doubled year on year, driven almost entirely by amounts owed by group companies. Track the ageing of these intercompany balances and ensure they do not become effectively non-recoverable. -
Maintain filing discipline.
Continue submitting accounts and confirmation statements on time. Good regulatory hygiene preserves credibility with suppliers, lenders, and the parent company.